Dr. Lisa Cibik, AIO Director of Cataract Services, was the first Ophthalmologist in Western Pennsylvania to implant the AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL).
AIO is excited to continue to be the leader in technology on the Western side of Pennsylvania in the Ophthalmology Industry by introducing new innovative technology to their practice.
Alcon, the global leader in eye care announced the Food and Drug Administration (FDA) approval and its initial commercial launch of AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL), the first and only trifocal lens for U.S. patients undergoing cataract surgery. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery.
PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to high-quality distance vision in a range of lighting conditions. The new lens uses ENLIGHTEN® Optical Technology, a proprietary design that optimizes intermediate vision without compromising near and distance vision. Available in spherical and toric designs, PanOptix is built on Alcon’s proven AcrySof IQ IOL platform that has been implanted in more than 120 million eyes globally.
“We are proud to bring this new class of IOLs to the largest eye care market in the world,” said David J. Endicott, Chief Executive Officer of Alcon. “We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses postsurgery.”
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses.
More than ninety-nine percent of PanOptix patients in the FDA clinical study said they would choose the same lens again.
More than 4 million cataract surgeries are performed each year in the U.S., which is projected to increase by more than 16 percent by the end of 2024. The presbyopia-correcting IOL market is expected to grow 60 percent by the end of 2024.
Cataracts are the most common age-related eye condition and the leading cause of preventable blindness. Twenty million people in the U.S. age 40 and older have cataracts. Cataracts are treated by removing the eye’s cloudy natural lens and surgically replacing it with an intraocular lens or IOL. More than 98 percent of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.
Become a PanOptimist and seize life without cataracts with the PanOptix® Trifocal Lens. To learn more about your cataract surgery options and if the PanOptix® Lens is right for you, give us a call to schedule your consultation.